Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology · Autoimmune Brainstem Encephalitis

The Role of Antibodies and Cancer Risk

At a Glance

In autoimmune brainstem encephalitis, the antibody type helps doctors estimate cancer risk and choose targeted screening. Intracellular antibodies such as KLHL11, Ma2, Hu, and Ri have stronger cancer links, while some cell-surface antibodies are less often associated with cancer.

In autoimmune brainstem encephalitis, your immune system produces antibodies—special proteins that usually fight germs—that mistakenly target your brain. Identifying the specific “name” of the antibody is one of the most important steps in your care, because it acts as a roadmap for your treatment and tells your doctors where to look for potential underlying causes, like a hidden tumor [1][2]. Note that some patients remain antibody-negative.

Two Main Categories of Antibodies

Doctors divide these antibodies into two main groups based on where their target “lives” on a brain cell. This location acts as a prognostic and mechanistic clue, though it is not a rigid treatment rule or a guarantee of recovery.

  • Cell-Surface Antibodies: These target the “outside” or doors of the brain cells (like MOG, GQ1b, or Glycine receptor). These conditions may respond favorably to immunotherapy, though individual outcomes vary. Note that MOG-associated disease and GQ1b-ganglioside syndromes represent distinct clinical syndromes, not interchangeable forms of isolated brainstem encephalitis [3][4].
  • Intracellular (Onconeural) Antibodies: These target the “inside” of the brain cells (like KLHL11, Hu, Ri, or Ma2). These antibodies are usually just a biomarker indicating that the immune system is using aggressive T cells to attack the brain cells from the inside [1][5]. Because the damage can be more persistent, these conditions are sometimes harder to treat and carry stronger risk patterns linked to cancer [3][6].

The “Paraneoplastic” Link: Cancer as a Trigger

Many of these antibodies are paraneoplastic, meaning they are triggered by a cancer elsewhere in the body. The immune system tries to fight the cancer, but the cancer cells look so much like your brainstem cells that the immune system gets confused and attacks both [7].

Two antibodies carry particular risk patterns for testicular germ-cell tumors (like seminoma):

  • KLHL11: This is a major biomarker for men with brainstem inflammation. In one selected specialty cohort, over 80% of men with this antibody either had an active testicular tumor or evidence of a “burned-out” tumor (where the immune system attacked the tumor) [8][9].
  • Ma2: This antibody is also linked to testicular tumors, as well as lung or breast cancers in some cases [10].

Antibody-Specific Cancer Risks

Your antibody provides risk patterns that tell your doctor where to “hunt” for a tumor:

  • Hu (ANNA-1): Linked to small-cell lung cancer [11].
  • Ri (ANNA-2): Linked to breast cancer in women and lung cancer in men [12].
  • Amphiphysin: Linked to breast and small-cell lung cancers [13].
  • GQ1b / MOG / GFAP: These are less likely to be linked to cancer and are often “stand-alone” autoimmune issues [14][15].

Actionable Care: Cancer Screening

Because cancer risk varies substantially by antibody, age, sex, phenotype, and assay quality, screening must be a clinician-directed risk-based approach rather than a rigid universal checklist. Depending on your risk profile and current paraneoplastic guidelines, your care team may select from:

  • Initial Imaging: This may include a CT scan of the chest, abdomen, and pelvis [11].
  • Advanced Scans: A specialized scan (FDG-PET/CT) that looks for metabolic activity may be used if appropriate for your risk category [16].
  • Targeted Scans: Testicular ultrasound for men; mammogram and breast ultrasound for women, based on symptoms and antibody type [17][13].
  • Long-term Surveillance: If the first round is negative but you carry a high-risk antibody, follow-up intervals and duration (such as repeat imaging) will be tailored by your specialist guidelines, as tumors can be tiny and invisible on the first scan [18][19].

Treating the underlying cancer, if found, is often a helpful way to stabilize the immune system, though neurological injury may be irreversible [7][20].

Common questions in this guide

What does an intracellular antibody mean in autoimmune brainstem encephalitis?
An intracellular antibody targets proteins inside nerve cells and often serves as a marker that specialized immune cells called T cells are attacking those cells. These cases can be harder to treat and are more strongly associated with an underlying cancer than some cell-surface antibody syndromes, although the result does not prove that cancer is present.
Which antibody results are most linked to an underlying cancer?
KLHL11 and Ma2 are linked especially with testicular germ-cell tumors, while Ma2 can also occur with lung or breast cancer. Hu, also called ANNA-1, is linked to small-cell lung cancer, and Ri, also called ANNA-2, is linked to breast cancer in women and lung cancer in men. Amphiphysin is associated with breast and small-cell lung cancers.
Does a positive antibody test mean I have cancer?
No. A positive result can identify a cancer-associated risk pattern, but it does not diagnose cancer, and the level of risk depends on the antibody, age, sex, clinical symptom pattern, and test quality. Your care team should choose screening based on your individual risk.
What cancer screening might I need after an antibody-positive result?
Depending on your risk profile, clinicians may use CT scans of the chest, abdomen, and pelvis, an FDG-PET/CT scan, or targeted imaging such as testicular ultrasound, mammography, or breast ultrasound. If initial tests are negative and the antibody carries high risk, your specialist may recommend repeat imaging over a tailored period. There is no single screening schedule for everyone.
How does the antibody type affect my response to immunotherapy?
Conditions associated with cell-surface antibodies may respond more favorably to immunotherapy, but individual outcomes vary. Intracellular antibody syndromes can be harder to treat because immune-cell injury to neurons may persist. The antibody category helps guide expectations but cannot guarantee recovery.
Can autoimmune brainstem encephalitis occur if antibody tests are negative?
Yes. Some patients remain antibody-negative, so a negative test does not by itself rule out autoimmune brainstem encephalitis. Clinicians interpret the result alongside symptoms and other clinical findings.
Does it matter whether the antibody was found in blood or spinal fluid?
It can matter. Your neurologist interprets whether the antibody was found in blood, spinal fluid, or both together with the test method and your clinical picture. The location of the antibody result alone does not determine the diagnosis.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-specific autoimmune brainstem encephalitis with characteristic antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific antibody was found in my tests, and is it a 'cell-surface' or 'intracellular' type?
  2. 2.Does my antibody result mean I have a higher risk of an underlying cancer, and what specific types of cancer are we looking for?
  3. 3.What clinician-directed, risk-stratified cancer screening approach do you recommend for my specific situation?
  4. 4.Given my specific antibody, how likely is it that my symptoms will improve with immunotherapy?
  5. 5.Was my antibody found in my blood, my spinal fluid, or both? Does that change the diagnosis?

References

References (20)
  1. 1

    Paraneoplastic Neurologic Disorders.

    Zekeridou A

    Continuum (Minneapolis, Minn.) 2024; (30(4)):1021-1051 doi:10.1212/CON.0000000000001449.

    PMID: 39088287
  2. 2

    Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

    Graus F, Vogrig A, Muñiz-Castrillo S, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2021; (8(4)) doi:10.1212/NXI.0000000000001014.

    PMID: 34006622
  3. 3

    Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management.

    Sechi E, Flanagan EP

    Frontiers in neurology 2021; (12()):673339 doi:10.3389/fneur.2021.673339.

    PMID: 34305787
  4. 4

    Autoimmune encephalitis : Part 1 (Epidemiology, Pathophysiology and Clinical spectrum).

    Hiesgen J, Schutte C

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2023; (113(3)):116-121 doi:10.7196/SAMJ.2023.v113i3.780.

    PMID: 36876355
  5. 5

    Paraneoplastic neurological syndromes: a practical approach to diagnosis and management.

    Binks S, Uy C, Honnorat J, Irani SR

    Practical neurology 2022; (22(1)):19-31 doi:10.1136/practneurol-2021-003073.

    PMID: 34510016
  6. 6

    Differences and diversity of autoimmune encephalitis in 77 cases from a single tertiary care center.

    Saraya AW, Worachotsueptrakun K, Vutipongsatorn K, et al.

    BMC neurology 2019; (19(1)):273 doi:10.1186/s12883-019-1501-5.

    PMID: 31694559
  7. 7

    Paraneoplastic encephalitis: clinically based approach on diagnosis and management.

    Vaišvilas M, Ciano-Petersen NL, Macarena Villagrán-García MD, et al.

    Postgraduate medical journal 2023; (99(1173)):669-678 doi:10.1136/postgradmedj-2022-141766.

    PMID: 37389581
  8. 8

    Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis.

    Dubey D, Wilson MR, Clarkson B, et al.

    JAMA neurology 2020; (77(11)):1420-1429 doi:10.1001/jamaneurol.2020.2231.

    PMID: 32744608
  9. 9

    Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis.

    Vogrig A, Péricart S, Pinto AL, et al.

    Brain communications 2021; (3(3)):fcab185 doi:10.1093/braincomms/fcab185.

    PMID: 34557666
  10. 10

    Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes.

    Ortega Suero G, Sola-Valls N, Escudero D, et al.

    Neurologia 2018; (33(1)):18-27 doi:10.1016/j.nrl.2016.05.010.

    PMID: 27460184
  11. 11

    Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.

    Villagrán-García M, Farina A, Muñiz-Castrillo S, et al.

    Brain communications 2023; (5(5)):fcad247 doi:10.1093/braincomms/fcad247.

    PMID: 37794924
  12. 12

    Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review.

    Chen Y, Wu C, Liu X, et al.

    Journal of neurology 2026; (273(4)).

    PMID: 41894019
  13. 13

    Breast cancer-associated opsoclonus-myoclonus syndrome: a case report.

    Kostoglou A, Vlastos D, Bakalis A, Ghosh D

    World journal of surgical oncology 2021; (19(1)):328 doi:10.1186/s12957-021-02436-7.

    PMID: 34781971
  14. 14

    Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody.

    Yoshikawa K, Kuwahara M, Morikawa M, Kusunoki S

    Neurology(R) neuroimmunology & neuroinflammation 2020; (7(6)) doi:10.1212/NXI.0000000000000889.

    PMID: 32934014
  15. 15

    MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

    Jarius S, Kleiter I, Ruprecht K, et al.

    Journal of neuroinflammation 2016; (13(1)):281 doi:10.1186/s12974-016-0719-z.

    PMID: 27802825
  16. 16

    Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging.

    Opalińska M, Sowa-Staszczak A, Wężyk K, et al.

    Journal of clinical medicine 2022; (11(6)) doi:10.3390/jcm11061537.

    PMID: 35329862
  17. 17

    Paraneoplastic cerebellitis with Kelch-like protein 11 antibodies as an initial presentation for testicular seminoma.

    Mercer JS, Myers E, Labriola MK

    BMJ case reports 2025; (18(8)) doi:10.1136/bcr-2024-262710.

    PMID: 40759499
  18. 18

    Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.

    Mandel-Brehm C, Dubey D, Kryzer TJ, et al.

    The New England journal of medicine 2019; (381(1)):47-54 doi:10.1056/NEJMoa1816721.

    PMID: 31269365
  19. 19

    Clinical approach to diagnosis of paraneoplastic neurologic syndromes.

    Graus F

    Handbook of clinical neurology 2024; (200()):79-96 doi:10.1016/B978-0-12-823912-4.00007-4.

    PMID: 38494298
  20. 20

    Paraneoplastic Diseases of the Central Nervous System.

    Galli J, Greenlee J

    F1000Research 2020; (9()) doi:10.12688/f1000research.21309.1.

    PMID: 32194943

This page is for informational purposes only and does not constitute medical advice. It explains antibody-related cancer risk in autoimmune brainstem encephalitis; your neurology and oncology teams should interpret your results and screening plan.